~~<i id='E5438796C7'><strike id='E5438796C7'><tt id='E5438796C7'><pre id='E5438796C7'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：leisure time 2025-10-06 12:38:04 Page View：268

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wisconsin governor employs partial veto to fund schools for 4 centuries
Next article： Hepatitis C has a cure — but many Americans still lack access to it

explore

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

ReNAgade cuts staff seven months after raising $300 million

AdobeBiotechstartupReNAgadeTherapeuticsiscuttingstaffjustsevenmonthsafterraisingthelargestSeriesArou

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

What don’t we know about an Alzheimer’s drug side effect?

Illustration:AlexHogan/STAT;Photo:EisaiviaAPSincetheFDA’sapprovaloflecanemab(marketedasLeqembi)andMe